Advanced Biomed Inc. ADVB
in the State of Nevada. We operate through Advanced Biomed Taiwan and Advanced Biomed HK. Advanced Biomed Taiwan is responsible for the
main operation and the design and development of the company's primary technologies and products. Since our establishment in 2014,
we have been focusing on the integration of multiple interdisciplinary technologies and established our own microfluidic technology platform.
Utilizing the physical and molecular biological characteristics of tumor cells, we have developed various advanced and original research
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D | $909.8K | $880.2K | — |
| SG&A | $2.1M | $1.7M | — |
| Total operating expenses | $3.0M | $2.5M | — |
| Pre-tax income | -$3.3M | -$2.8M | — |
| Net income | -$3.3M | -$2.8M | — |
| EPS, basic | -0.16 | -0.14 | — |
| EPS, diluted | -0.16 | -0.14 | — |
| Shares, diluted (wtd. avg.) | 20.5M | 20.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | $2.9M | $2.6M | $2.6M |
| Total current assets | $6.0M | $3.1M | — |
| Property, plant and equipment | $331.3K | $524.5K | — |
| Other intangibles | — | $119.0K | — |
| Total assets | $6.5M | $4.5M | — |
| Accounts payable | $632.7K | $620.5K | — |
| Total current liabilities | $2.9M | $2.7M | — |
| Total liabilities | $3.0M | $2.8M | — |
| Retained earnings | -$19.2M | -$16.0M | — |
| Total equity | $3.5M | $1.7M | $1.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | -$5.8M | -$2.1M | — |
| Depreciation and amortisation | $224.8K | $268.3K | — |
| Capital expenditure | $31.6K | $74.1K | — |
| Investing cash flow | -$31.6K | -$74.1K | — |
| Financing cash flow | $5.9M | $1.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-25-097465.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Net income | — | -$2.8M | -$3.3M |
Recent filings and events
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Material agreement signed Item 1.01
- Material agreement signed Item 1.01
- Officer or director change Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8071
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $58.23B | — | 35.9% |
| DGX | QUEST DIAGNOSTICS INC | $26.70B | 27.6x | 11.8% |
| LH | LABCORP HOLDINGS INC. | $26.68B | 31.4x | 7.2% |
| GH | Guardant Health, Inc. | $22.69B | — | 32.9% |
| CAI | Caris Life Sciences, Inc. | $9.04B | — | 97.0% |
| GRAL | GRAIL, Inc. | $5.92B | — | 17.2% |
| RDNT | RadNet, Inc. | $5.54B | — | 11.5% |
| BLLN | BillionToOne, Inc. | $5.00B | 769.8x | 100.0% |